ATE197670T1 - Parenterales busulfan zur behandlung von malignen krankheiten - Google Patents

Parenterales busulfan zur behandlung von malignen krankheiten

Info

Publication number
ATE197670T1
ATE197670T1 AT94929116T AT94929116T ATE197670T1 AT E197670 T1 ATE197670 T1 AT E197670T1 AT 94929116 T AT94929116 T AT 94929116T AT 94929116 T AT94929116 T AT 94929116T AT E197670 T1 ATE197670 T1 AT E197670T1
Authority
AT
Austria
Prior art keywords
treatment
busulfan
malignant diseases
parenteral
parenteral busulfan
Prior art date
Application number
AT94929116T
Other languages
English (en)
Inventor
Borje S Andersson
Harshal P Bhagwatwar
Diana Shu-Lian Chow
Original Assignee
Univ Texas
Univ Houston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22442547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE197670(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Univ Houston filed Critical Univ Texas
Application granted granted Critical
Publication of ATE197670T1 publication Critical patent/ATE197670T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94929116T 1993-09-30 1994-08-30 Parenterales busulfan zur behandlung von malignen krankheiten ATE197670T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/129,995 US5430057A (en) 1993-09-30 1993-09-30 Parenteral busulfan for treatment of malignant disease
PCT/US1994/009748 WO1995008991A1 (en) 1993-09-30 1994-08-30 Parenteral busulfan for treatment of malignant disease

Publications (1)

Publication Number Publication Date
ATE197670T1 true ATE197670T1 (de) 2000-12-15

Family

ID=22442547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929116T ATE197670T1 (de) 1993-09-30 1994-08-30 Parenterales busulfan zur behandlung von malignen krankheiten

Country Status (13)

Country Link
US (2) US5430057A (de)
EP (1) EP0725637B1 (de)
JP (1) JP3599285B2 (de)
KR (1) KR100371826B1 (de)
AT (1) ATE197670T1 (de)
AU (1) AU694141B2 (de)
CA (1) CA2171738C (de)
DE (1) DE69426334T2 (de)
DK (1) DK0725637T3 (de)
ES (1) ES2153862T3 (de)
GR (1) GR3035447T3 (de)
PT (1) PT725637E (de)
WO (1) WO1995008991A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6734338B1 (en) 1997-11-14 2004-05-11 Cedars-Sinai Medical Center Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
AU761758B2 (en) * 1997-11-14 2003-06-12 Cedars-Sinai Medical Center Transfection and transfer of male germ cells for generation of transgenic species
US7294755B1 (en) 1997-11-14 2007-11-13 Cedars-Sinai Medical Center Genetic modification of male germ cells for generation of transgenic species and genetic therapies
US20080131498A1 (en) * 1998-06-18 2008-06-05 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
WO1999065481A1 (en) * 1998-06-18 1999-12-23 Karolinska Innovations Ab Liposomal formulations of busulphan
US7351427B2 (en) * 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7122640B2 (en) * 2002-06-10 2006-10-17 Phynexus, Inc. Open channel solid phase extraction systems and methods
EP1524997A1 (de) * 2002-06-26 2005-04-27 Pharmacia Corporation Stabile flüssige parenterale parecoxibzusammensetzungen
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
BRPI0418798A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit
JP4486994B2 (ja) * 2004-09-15 2010-06-23 サラダックス バイオメディカル インコーポレイテッド ブスルファンイムノアッセイ
WO2008157785A1 (en) * 2007-06-20 2008-12-24 University Of Louisville Research Foundation, Inc. T cell depleting compositions useful for treating cancer
CN102151257B (zh) * 2011-02-17 2015-03-04 四川科瑞德凯华制药有限公司 一种白消安注射剂及其制备方法
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
CN103446045B (zh) * 2012-06-01 2015-08-12 四川科瑞德凯华制药有限公司 一种稳定的白消安注射剂
WO2014089957A1 (zh) * 2012-12-11 2014-06-19 四川科瑞德凯华制药有限公司 一种稳定的白消安注射剂
CN105726467A (zh) * 2014-12-09 2016-07-06 四川科瑞德制药有限公司 一种白消安注射液及其制备方法
CN110831588B (zh) * 2017-05-03 2023-06-27 锡德克斯药物公司 包含环糊精和白消安的组合物
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用
WO2020205838A1 (en) * 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3109783C2 (de) * 1981-03-13 1987-04-02 Schwarz GmbH, 4019 Monheim Verfahren zur Herstellung einer ethanolfreien Nitroglycerinlösung mit einer Konzentration von etwa 1 mg Nitroglycerin/ml
JPS6461429A (en) * 1987-08-29 1989-03-08 Akio Hagiwara Remedy for cancer
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs

Also Published As

Publication number Publication date
US5559148A (en) 1996-09-24
DE69426334D1 (de) 2000-12-28
AU7829094A (en) 1995-04-18
KR960704543A (ko) 1996-10-09
EP0725637A1 (de) 1996-08-14
DK0725637T3 (da) 2001-03-26
EP0725637B1 (de) 2000-11-22
GR3035447T3 (en) 2001-05-31
ES2153862T3 (es) 2001-03-16
DE69426334T2 (de) 2001-03-29
AU694141B2 (en) 1998-07-16
PT725637E (pt) 2001-06-29
CA2171738C (en) 2002-07-16
CA2171738A1 (en) 1995-04-06
US5430057A (en) 1995-07-04
JP3599285B2 (ja) 2004-12-08
WO1995008991A1 (en) 1995-04-06
JPH09502996A (ja) 1997-03-25
KR100371826B1 (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
BG101118A (en) Therapeutical compounds
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
DK0539479T3 (da) Heterocykliske forbindelser
HU907959D0 (en) Medical preparations
ATE170075T1 (de) Antivirales arzneimittel enthaltend prostratin
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
TR199901385T2 (xx) Piperidin t�revleri.
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
YU169090A (sh) Tetra hidroimidazo (1,4) benzodiazepini
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
UA36093A (uk) Спосіб лікування хронічного бронхіту
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification